




Article

Would *Cutibacterium acnes* Be the Villain for the Chronicity of Low Back Pain in Degenerative Disc Disease? Preliminary Results of an Analytical Cohort

Vinícius Magno da Rocha ¹, Carla Ormundo Gonçalves Ximenes Lima ², Gustavo Baptista Candido ³, Keila Mara Cassiano ⁴, Kai-Uwe Lewandrowski ^{5,6}, Eliane de Oliveira Ferreira ^{2,*} and Rossano Kepler Alvim Fiorelli ¹

- ¹ Department of General and Specialized Surgery, School of Medicine, Federal University of the State of Rio de Janeiro (Unirio), Rio de Janeiro 21941-901, Brazil
- ² Department of Medical Microbiology, Institute of Microbiology Paulo de Góes, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-901, Brazil
- ³ Niterói D'Or Hospital, Niterói 24230-251, Brazil
- ⁴ Department of Statistics, Institute of Mathematics, Fluminense Federal University (UFF), Niterói 24220-008, Brazil
- ⁵ Center for Advanced Spine Care of Southern Arizona, Tucson, AZ 85712, USA
- ⁶ Surgical Institute of Tucson, Tucson, AZ 85711, USA
- * Correspondence: eliane_ferreirarj@micro.ufjf.br; Tel.: +55-21-9-7199-2634

Abstract: In the last decade, several studies have demonstrated *Cutibacterium acnes* colonization in intervertebral discs (IVDs) in patients with lumbar disc degeneration (LDD) and low back pain (LBP), but the meaning of these findings remains unclear. Being aware of this knowledge gap, we are currently conducting a prospective analytical cohort study with LBP and LDD patients undergoing lumbar microdiscectomy and posterior fusion. The IVDs samples collected during the surgeries are subjected to a stringent analytical protocol using microbiological, phenotypic, genotypic, and multiomic techniques. Additionally, pain-related scores and quality-of-life indexes are monitored during patient follow-up. Our preliminary results for 265 samples (53 discs from 23 patients) revealed a *C. acnes* prevalence of 34.8%, among which the phylotypes IB and II were the most commonly isolated. The incidence of neuropathic pain was significantly higher in the colonized patients, especially between the third and sixth postoperative months, which strongly suggests that the pathogen plays an important role in the chronicity of LBP. The future results of our protocol will help us to understand how *C. acnes* contributes to transforming inflammatory/nociceptive pain into neuropathic pain and, hopefully, will help us to find a biomarker capable of predicting the risk of chronic LBP in this scenario.

Keywords: intervertebral disc; low back pain; discogenic pain; chronic pain; *Cutibacterium acnes*; neuropathic pain



Citation: da Rocha, V.M.; Lima, C.O.G.X.; Candido, G.B.; Mara Cassiano, K.; Lewandrowski, K.-U.; de Oliveira Ferreira, E.; Fiorelli, R.K.A. Would *Cutibacterium acnes* Be the Villain for the Chronicity of Low Back Pain in Degenerative Disc Disease? Preliminary Results of an Analytical Cohort. *J. Pers. Med.* **2023**, *13*, 598. <https://doi.org/10.3390/jpm13040598>

Academic Editor: Salvatore Rinaldi

Received: 7 February 2023

Revised: 20 March 2023

Accepted: 26 March 2023

Published: 29 March 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Low back pain (LBP) is a highly prevalent complaint among the population. It has several consequences for the patient and for society, such as physical and psychological limitations, drug abuse, absenteeism from work, and the potential to overload social security and health systems [1–3]. It is a multifactorial etiological condition whose incidence is about five times higher in patients with lumbar disc degeneration (LDD) [4–9].

In the last decade, advances in molecular identification and microbiological culture techniques have redirected the researchers' attention to the isolation of low-virulence pathogens in different musculoskeletal conditions, such as aseptic failures of surgical implants and intervertebral discs (IVDs) degeneration [10–18]. Among these pathogens, the one that is the most isolated in patients with LDD is *Cutibacterium acnes*, which has a

prevalence rate of around 40% [19–21]. Given the public health importance of LBP and its high association with LDD, there has been extensive research to understand the role of *C. acnes* in this scenario.

Studies evaluating Modic changes (MCs) are the most common in relating LDD to *C. acnes* colonization [10,22–25]. MCs represent fissures in the endplates of the vertebrae and are common magnetic resonance imaging (MRI) findings in patients with LDD [26,27]. Substantial recent evidence has correlated MCs with IVD colonization by *C. acnes*, but these findings are not unanimous among studies [19,28,29]. Rajasekaran et al. applied proteomic techniques to demonstrate how host defense proteins and other proteins are indicative of bacterial viability and proliferation in IVDs colonized by *C. acnes*. These authors integrated the presence of the pathogen with mechanical factors, such as the occurrence of fissures in the endplates, within what they called the unified hypothesis of disc degeneration [30]. Capoor et al. demonstrated the positive effect of *C. acnes* in IVD cell cultures on the expression of IL-1 β and other host defense molecules related to the neo-innervation of the annulus fibrosus and the degradation of the extracellular matrix (ECM) of IVDs [31]. Other authors have indicated that such responses were conditioned by the immune profile of the host and the virulence mechanisms of the *C. acnes* strain; some biofilm-producing phylotypes use this feature to remain inert to defense cells within IVDs, while others produce ECM degradation enzymes in IVDs and activate inflammatory cascades through the Toll-like receptor system [31–36].

Although there is growing evidence pointing to the active role of *C. acnes* in IVD de-generation pathways and the activation of inflammatory cascades, so far, the available literature has not fully explained the mechanisms related to the generation and/or chronification of LBP in patients with LDD. There is a dearth of studies that aim to monitor the evolution of patients' pain complaints, especially after IVD collection and not just at the time of enrollment for microbiological investigation. There are no standardized or reproducible protocols, so the data produced by analytical cohorts can barely be used in trustworthy reviews and meta-analyses. There are also few alternatives to compensate for the lack of "normal" control IVDs that, despite bacterial colonization, present the physiological changes of aging, which will vary according to genetics and an individual's choices throughout their life.

Aware of these limitations, our research group designed a prospective cohort study for the follow-up of patients with LBP and LDD. In addition to the control of clinical variables before and after sampling (surgical procedure in which the IVD specimens are obtained), the design of this cohort also houses an analytical study that brings together microbiological, molecular, and multiomic techniques in an unprecedented way [37]. This protocol was registered at ClinicalTrials.gov, has been validated, and is already in progress.

Given the topic's relevance, this manuscript aims to present the preliminary microbiological results of this research and to correlate them with the clinical profile of the patients being followed up.

2. Materials and Methods

This cohort study integrates clinical and analytical data and is in progress at the Spine Surgery Center of São Matheus Hospital, in partnership with the Gaffrée and Guinle University Hospital and the Laboratory of Anaerobic Biology, at the Institute of Microbiology Paulo de Góes (IMPG) of the Federal University of Rio de Janeiro (UFRJ).

Patients with LBP for at least 3 months and findings confirming LDD on MRI were recruited and selected for surgical treatment through microdiscectomy and lumbar fusion. The procedures were performed in a single hospital by the same team of surgeons. All patients included in the study were informed about the research and freely agreed to participate before signing the Informed Consent Form for the study. The selection criteria for the study are listed in Table 1.

Table 1. Selection Criteria of Patients.

| Inclusion | Exclusion |
|--------------------------------------------------------------|-----------------------------------------------|
| Age between 18 and 65 years | History of previous lumbar spine surgery |
| LBP ^a lasting more than 3 months | Chemotherapy or pulse therapy with corticoids |
| MRI ^b performed less than 6 months before surgery | History of spinal infection |
| Failure of conservative treatment for at least 6 weeks | Previous intradiscal therapies |

^a—Low back pain; ^b—Magnetic resonance imaging.

The patients were monitored by a team of specialists in pain and/or spinal surgery for at least 3 months before surgery and for the first 6 months after surgery. During patient recruitment and follow-up, we collected demographic, clinical, and imaging data (Table 2). Only the group of researchers involved with the laboratory analyses had access to the microbiological results before the end of the 6th postoperative month.

Table 2. Patients’ Collected Data.

| Data | Moment of Collection | | | |
|--------------------------------------------------------|----------------------|-----------------|----------------|----------------|
| | Enrollment. | 1st Postop. Mo. | 3rd Postop. Mo | 6th Postop. Mo |
| Age, gender, BMI ^a , No. of levels | X | | | |
| Sedentary lifestyle, smoking | X | | | |
| SAH ^b , diabetes, other comorbidities | X | | | |
| MRI ^c (Modic changes) | X | | | |
| VNS ^d , DN4 ^e , ODI ^f | X | X | X | X |
| EuroQol questionnaire (EQ-5D) | X | | | X |
| Time off work | | X | X | X |

^a—Body mass index; ^b—Systemic arterial hypertension; ^c—Magnetic resonance imaging; ^d—Visual numeric scale; ^e—Douleur neuropathique questionnaire; ^f—Oswestry Disability Index.

Intravenous antibiotic prophylaxis was performed exclusively during the surgery for all the patients (cefazolin 1 g, repeated every 4 h for the duration of the surgery), as is the hospital protocol of cutaneous asepsis using 2% chlorhexidine gluconate degerming solution and 0.5% alcoholic solution of chlorhexidine gluconate.

During surgery, five tissue fragments were collected for each IVD addressed. A set of sterile surgical tweezers was used for collection, with one set being used for each tissue fragment. Immediately after collection, the clamp with the sample was handed over to a member of the laboratory who was also present in the operating room during the procedure. Each sample was inoculated into a flask containing thioglycolate culture medium (Merck, Rio de Janeiro, Brazil) containing 20 glass beads in each tube. After sampling, the vials containing the clinical specimens were kept at room temperature and were transported to the laboratory of Biology of Anaerobes at the Federal University of Rio de Janeiro (UFRJ) (Instituto de Microbiologia Paulo de Góes- IMPG, Medical Microbiology Department, UFRJ) within a maximum period of 2 h.

The tubes containing IVD fragments undergo vortexing (Even EVX2800-BI[®], Curitiba, Brazil) for 15 s. All tubes were kept in a bacteriological incubator (from 35 °C to 37 °C), and after 24 h, the first subculture was performed. Using a 100 µL bacteriological loop, aliquots of thioglycolate were removed and seeded: one onto a blood agar base and another on anaerobic blood agar. The first plate was incubated under a capnophilic atmosphere, and a second plate was kept in strict anaerobiosis using an anaerobic jar or Glove Box (Coy Labs[®], Grass Lake, MI, USA). The plates were read after 24 h, and, in case of growth, the colonies were identified in the MALDI-TOF MS (Bruker[®], Billerica, MA, USA). In the absence of growth, they were reincubated, and a new reading was performed after 72 h. The same procedure was used for all of the thioglycolate vials (totaling 10 vials for each level approached). The thioglycolate tubes containing the clinical specimens were kept under incubation (35 °C to 37 °C) for at least 14 days. The subculture procedure was

performed after 72 h and then every 3 days, with the last being performed on the 14th day of incubation in the same solid culture media and atmospheres used in the first 24 h.

The analyses of the samples were carried out sequentially according to the performance of the surgical procedures in the selected participants. Once the pathogen in the culture media has been identified, we proceed with its phenotypic and genotypic characterization by using MALDI-TOF MS (Bruker Biotyper®, Bremen, Germany) and r-16S DNA analysis using the Multiplex Touch-Down PCR technique (species-specific and Filotyping PCR), respectively.

We perform multiomic analyses for: (1) the identification of prokaryotic proteins that may be acting as molecular patterns associated with pathogens (PAMPs) or damages (DAMPs) in the host response (proteomics) and for (2) the definition of a metabolomic signature for patients with LBP who have LDD associated with *C. acnes* colonization (metabolomics). Variables distributions in the negative and positive to *C. acnes* groups were compared appropriately by the Fisher’s exact test or Mann–Whitney tests.

3. Results

At the time of writing this manuscript, the microbiological analyses of 265 lumbar IVD samples obtained from 23 patients (52.2% female and 47.8% male) with a mean age of 46.5 years had been completed (SD 10.2; median 44.0). No clinical disease was reported with a frequency greater than 50% (SAH, diabetes, endocrine, or vascular diseases). Obesity was identified in 43.5% of the patients (seven with grade I and three with grade II). Smoking was reported by 39.1% of the patients (consumption of at least one cigarette/day over the course of 1 year), and 60.9% declared themselves to have a sedentary lifestyle (light physical activity of less than 150 min per week). The patients’ baseline characteristics are listed in Table 3.

Table 3. Baseline Patients’ Characteristics Means According to Microbiological Profile.

| Variable | Category | Global (n = 23) | <i>C. acnes</i> (–) (n = 15) | <i>C. acnes</i> (+) (n = 8) | p-Value |
|------------------------|---------------------|-----------------|------------------------------|-----------------------------|--------------------|
| Gender | Female | 52.2% | 60.0% | 37.5% | 0.400 ^a |
| | Male | 47.8% | 40.0% | 62.5% | |
| BMI | Normal weight | 21.7% | 20.0% | 25.0% | 0.728 ^b |
| | Overweight | 34.8% | 40.0% | 25.0% | |
| | Obesity I | 30.4% | 26.7% | 37.5% | |
| | Obesity II | 13.0% | 13.3% | 12.5% | |
| Comorbidities | Diabetes | 47.8% | 33.3% | 75.0% | 0.089 ^a |
| | Obesity | 43.5% | 40.0% | 50.0% | 0.667 ^a |
| | SAH ^c | 39.1% | 40.0% | 37.5% | 1.000 ^a |
| Bad Habits | Smoking | 39.1% | 26.7% | 62.5% | 0.179 ^a |
| | Sedentary Lifestyle | 60.9% | 53.3% | 75.0% | 0.400 ^a |
| Preop. Pain | Sciatica | 56.5% | 53.3% | 62.5% | 1.000 ^a |
| | Mechanics | 43.5% | 46.7% | 37.5% | |
| Preop DN4 ^d | ≤1 | 26.1% | 26.7% | 25.0% | 0.899 ^a |
| | 2 | 47.8% | 40.0% | 62.5% | |
| | 3 | 21.7% | 26.7% | 12.5% | |
| | ≥4 | 4.3% | 6.7% | 0.0% | |
| Preop ODI ^e | Minimal/Moderate | 47.8% | 53.3% | 37.5% | 0.294 ^b |
| | Severe/Crippled | 52.2% | 46.7% | 62.5% | 0.667 ^a |

^a—Fisher’s exact test; ^b—Mann–Whitney test; ^c—Systemic arterial hypertension; ^d—Douleur neuropathique questionnaire; ^e—Oswestry Disability Index.

3.1. Microbiological Analyses

Culture results are available for the 265 IVD samples (a total of 53 discs collected in 23 patients). *C. acnes* was isolated in discs from 34.8% of the patients and more frequently

among men (62.5%). The number of samples collected from each patient ranged from 5 to 20, totaling 265 samples, with an average of 11.5 samples collected per patient. In 160 samples from 15 patients, no positive samples were found. The 8 positive patients had 105 samples together, of which 79 were positive. Therefore, it is estimated that 24.8% of samples from positive patients do not show a positive result, showing the need to investigate several samples per patient (at least $1/0.752 = 1.3$ samples from each patient). Therefore, it is recommended to collect at least 2 samples from each patient for this investigation. The number of positive samples from each positive patient ranged from 2 to 20, averaging 9.9 positive samples from each positive patient. Table 4 brings together the main statistics on the isolation of *C. acnes* from the IVD samples.

Table 4. *Cutibacterium acnes* isolation statistics according to the number of patients included in the study.

| | |
|-------------------------------------------------|-------|
| Number of Patients | 23 |
| Number of evaluated discs | 53 |
| Number of discs samples | 265 |
| Number of <i>C. acnes</i> positive patients | 8 |
| Number of <i>C. acnes</i> positive discs | 18 |
| Number of <i>C. acnes</i> positive samples | 79 |
| Prevalence of <i>C. acnes</i> positive patients | 34.8% |

Phylotypes IB and II were found the most frequently in the colonized patients, being isolated in five and four patients, respectively; these two phylotypes jointly colonized 42.9% of the positive samples. The IA1 and IA2 phylotypes were isolated less frequently, being in mutual association in one patient and associated with the IB and/or II phylotypes in three other patients. In one of the patients colonized by *C. acnes*, phylotyping was not possible due to the death of the strains. Figure 1 graphically illustrates the distribution of the phylotypes in positive IVDs.




Figure 1. Frequency of *Cutibacterium acnes* phylotypes isolated.

3.2. Preoperative Features

All of the patients had LBP (43.5% mechanical pain and 56.5% sciatica pain), and an indication for surgical intervention was the failure of conservative treatment. The mean duration of symptoms before surgery was 12.1 months (SD 7.4; median 12 months), which was higher among the patients with sedentary lifestyles, patients with SAH, and those with mechanical pain (p -values of Mann–Whitney test lower than 5%). None of the patients had a motor deficit, and neuropathic pain was only identified in one of them (score greater than 4 on the DN4 questionnaire) during the preoperative clinical evaluation. Regarding the baseline characteristics (age, BMI, smoking, sedentary lifestyle, and clinical comorbidities), there was no significant difference between the groups with positive and negative cultures (Mann–Whitney tests and Fisher’s exact tests comparing the distributions of the two groups with p -values > 0.05). There was also no significant difference between these two groups in the preoperative Oswestry Disability Index (ODI) and EuroQol (EQ-5D) Quality of Life Scores (Mann–Whitney tests with p -values > 0.05).

3.3. Operative Features

In all of the patients, the surgical technique used was the same (microdiscectomy and transforaminal posterior fusion), with only the number of IVDs addressed in each patient varying (mean of 2.3—SD 1.0; median 3.0). The mean duration of the procedures was 3.7 h (SD 1.6; median 4.0), with an average of 1.6 h/level (SD 1.7; median 0.4). Regarding the duration of surgery and the number of IVDs addressed per patient, there was no significant difference between the groups with positive and negative cultures in the disk (Mann–Whitney test with p -values > 0.05). There were no clinical or operative complications for the patients included in this part of the study.

3.4. Postoperative Features

The mean length of hospital stay was longer in the patients with positive IVD cultures (7.4 days—SD 3.0; median 6.5 days) than in the patients with negative cultures (5.8 days—SD 1.6; median 6.0), but this difference was not statistically significant (Mann–Whitney test with p -value of 0.190). Time of opioid usage was significantly higher in the colonized patients (Mann–Whitney test with p -value of 0.001), as was the time off work (Mann–Whitney test with p -value of 0.0038).

Despite an overall improvement in VNS scores after surgery, when comparing the pain levels in patients with and without positive cultures, this improvement was not significant before the third postoperative month (Mann–Whitney tests with p -values > 5%). However, the VNS distributions from the third to the sixth months show a significant difference in the observed improvement between the two groups, being smaller in the positive group (Mann–Whitney tests with p -values < 5%). *C. acnes* colonization also seems to have influenced the occurrence of neuropathic pain in the postoperative period, with a significantly higher incidence among the patients with positive cultures, as seen in Figure 2 (87.5% in the sixth postoperative month according to the DN4 questionnaire and Fisher’s exact tests with p -values < 0.05). The neuropathic pain statistics at different moments during clinical follow-up are displayed in Table 5.

According to the functional assessment using ODI, we noted that there was an improvement in the global scores between the preoperative period and the sixth month after surgery, but this evolution was not statistically significant between the groups with and without positive cultures (Fisher’s exact and Mann–Whitney tests with p -values > 0.05).

From the assessments of the quality of life using the EQ-5D, the surgical intervention had a significant and positive impact on all of the assessment domains except for the self-care domain (Wilcoxon tests with p -values < 0.05). However, comparing the groups, we noticed that the presence of bacteria did not significantly interfere with the benefit of treatment before the sixth postoperative month (Mann–Whitney test with p -values > 0.05). Table 6 compares the medians of the EQ-5D domains.




Figure 2. Evolution of neuropathic pain incidence on the groups of patients negative and positive for *Cutibacterium acnes*. Frequency of Isolated Phylotypes.

Table 5. Neuropathic Pain Evaluation (DN4 Score).

| Variable | Category | Global (n = 23) | <i>C. acnes</i> (–) (n = 15) | <i>C. acnes</i> (+) (n = 8) | p-Value |
|------------------|----------|-----------------|------------------------------|-----------------------------|--------------------|
| Preoperative DN4 | Absent | 26.1% | 26.7% | 25.0% | 0.776 ^a |
| | Possible | 21.7% | 26.7% | 12.5% | |
| | Probable | 47.8% | 40.0% | 62.5% | |
| | Present | 4.3% | 6.7% | 0.0% | |
| DN4 1st month | Absent | 26.1% | 26.7% | 25.0% | 0.265 ^a |
| | Possible | 47.8% | 73.3% | 0.0% | |
| | Probable | 13.0% | 0.0% | 37.5% | |
| | Present | 13.0% | 0.0% | 37.5% | |
| DN4 3rd month | Absent | 43.5% | 60.0% | 12.5% | 0.019 ^a |
| | Possible | 0,0% | 0.0% | 0.0% | |
| | Probable | 17.4% | 10.0% | 12.5% | |
| | Present | 39.1% | 10.0% | 75.0% | |
| DN4 6th month | Absent | 60.0% | 60.0% | 0.0% | 0.011 ^a |
| | Possible | 6.7% | 6.7% | 0.0% | |
| | Probable | 13.3% | 13.3% | 12.5% | |
| | Present | 20.0% | 20.0% | 87.5% | |

^a—Mann–Whitney test.

3.5. Modic Changes

Just over half of the patients had MCs on preoperative MRI in at least one of the surgically approached levels (52.2%). Among the colonized patients, a significant association was identified between *C. acnes* and the occurrence of Modic type 1, while in the group without Modic, the frequency of *C. acnes* was 0,0%; in the ones with Modic, 66.7% were positive for *C. acnes* (Fisher’s exact test with a *p*-value of 0.001).

Table 6. EQ-5D Quality of Life Evaluation.

| Domain | Assessment | Median Score in the Domain | | |
|-----------------------|---------------------------|----------------------------|---------------------|-----------------------------------------------------------|
| | | <i>C. acnes</i> (–) | <i>C. acnes</i> (+) | <i>p</i> -Value ^b (Mann–Whitney ^b) |
| Mobility | Preoperative | 2.0 | 2.0 | 0.169 |
| | Postoperative (6th month) | 1.0 | 1.0 | 0.213 |
| | | 0.008 ^a | 0.025 ^a | - |
| Self-Care | Preoperative | 1.0 | 1.0 | 0.169 |
| | Postoperative (6th month) | 1.0 | 1.0 | 0.056 |
| | | 0.083 ^a | 0.157 ^a | - |
| Usual Activities | Preoperative | 1.5 | 1.5 | 0.875 |
| | Postoperative (6th month) | 1.0 | 1.0 | 1.000 |
| | | 0.025 ^a | 0.046 ^a | - |
| Pain or Discomfort | Preoperative | 2.0 | 3.0 | 0.591 |
| | Postoperative (6th month) | 1.0 | 2.0 | 0.825 |
| | | 0.001 ^a | 0.014 ^a | - |
| Anxiety or Depression | Preoperative | 2.00 | 2.00 | 0.548 |
| | Postoperative (6th month) | 1.00 | 1.00 | 0.131 |
| | | 0.008 ^a | 0.025 ^a | - |
| EQVas ^c | Preoperative | 80.0 | 90.0 | 1.000 |
| | Postoperative (6th month) | 30.0 | 60.0 | 0.875 |
| | | 0.001 ^a | 0.011 ^a | - |

^a—Wilcoxon test; ^b—Mann–Whitney test; ^c—Visual analogical scale of pain from EQ-5D.

4. Discussion

Our protocol revealed a *C. acnes* in disc prevalence (34.8%) and MC association (66.7%) close to the rates reported in the literature. The largest systematic review and meta-analysis ever published on the subject showed a prevalence of 28.7% in 1454 patients with disc degeneration [21]. This review gathered 14 studies whose methods varied both in sampling (number of samples per disc, column segment approached, and sampling technique), the culture media used, and the sample incubation time. This variance stems from the lack of a universal protocol for the isolation of *C. acnes* from IVD cultures, which hinders the performance of complementary analyses of the pathogen, such as strain phylotyping.

C. acnes has different and distinct evolutionary lineages, with the designated phylotypes IA1, IA2, IB, IC, II, and III being based on Multilocus Sequence Typing and Whole Genome Sequencing [38]. Each phylotype has a specific pathogenicity mechanism and produces virulence factors that, depending on the tissue they are colonizing, can trigger an inflammatory response or remain inert to the host’s immune system [34,39]. Rollason et al. highlighted the high proportion of phylotype II among positive IVD cultures from patients with LDD [40]; this phylotype produces the enzyme hyaluronate lyase (HYL), which degrades hyaluronic acid, an important component of ECM in IVDs, by contributing to its degeneration [41]. Moreover, hyaluronic acid degradation products have already been identified as activators of inflammatory pathways, with the production of molecules that integrate known discogenic pain pathways [42]. HYL has two variants, with the HYL-IB/II variant, which is found in phylotypes IB and II, being the most active [41,43]; phylotypes IB and II also secrete the cytotoxin CAMP-1 (Christie–Atkins–Munch–Petersen factor), which has a strong interaction with Toll-like receptor 2, amplifying the inflammatory response in the IVD microenvironment [33,44]. In an animal model study, Lan et al. demonstrated a positive effect of phylotypes IB and II on the expression of MMP-13 (Matrix Metalloproteinase 13), which is active in the degradation of collagen, an important component of the annulus fibrosus in IVDs [34]. Our preliminary results demonstrate a high frequency of

phylotypes IB and II, which were isolated in association in 42.9% of the positive samples. Although the number of patients monitored at present limits our conclusions, the patients colonized by phylotypes IB and II had the worst VNS and ODI scores in the sixth postoperative month. Since the IVD is not entirely removed during surgery, the remaining tissue could continue to harbor *C. acnes* and participate in the LBP chronification process.

Unprecedentedly, our study continues to monitor patients with LDD after IVD collection, and among the differences observed in the first part of our results, the one that caught our attention the most was the change in the pain patterns presented by the patients over the postoperative period. Among the colonized patients who had mechanical and/or nociceptive pain in the preoperative period, 37.5% manifested characteristics of neuropathic pain up to the third month after surgery, with an increase in this proportion to 87.5% by the sixth postoperative month. These data should direct studies to the mechanisms through which *C. acnes* may be acting in the modulation of pain generation and chronicity mechanisms. *C. acnes* has already been linked to elevated levels of neurotrophins related to the penetration of nociceptive neurons into the deeper layers of the annulus fibrosus in cell cultures [32] as well as to the stimulation of the expression of IL-1 β and other molecules associated with disc degeneration, inflammation, neo-innervation, and the activation of pain pathways [32,45–48]. Capoor et al. highlighted the secretion of hemolytic enzymes and pore-forming toxins by phylotypes IA, IB, and IC, which determines ionic influx and the chronic firing of action potentials in nociceptive neurons [49]. Freemont et al. demonstrated the presence of neurons that express the nocigenic Substance P in the internal annulus of the IVD and/or in the nucleus pulposus of patients with chronic LBP [50]. From these two authors' works, it is inferred that *C. acnes* colonization of IVDs chronically exposes the newly formed nociceptive neuron endings to pain triggers, resulting in chronic LBP. Future studies on these and other possible mechanisms involved in the chronicity of LBP in this type of patient profile represent further challenges. Mapping the phylogenetic epidemiological profile of IVD colonization in LDD and monitoring the responses of the host's immune system of the host for each manifested virulence factor are the next steps.

A variety of biological (e.g., genetics, immune response, infections, and age), psychological (e.g., depression, anxiety, and stress), and social (e.g., lack of monitoring, discrimination, and violence) factors are involved in conditions that generate chronic pain [51]. These factors determine changes in small molecules, known as metabolites, which can be identified and quantified using metabolomic techniques [52]. In a biological system, the metabolomic profile, that is, the type and number of metabolites in a sample, provides information on both the physiological and pathological processes of an individual [52,53]. In our study, based on the strains of isolated *C. acnes*, metabolomic analyses have been carried out to search for a metabolomic profile for chronic LBP related to the pathogen and LDD. Another multiomic analysis that has been carried out with isolated strains is proteomics analysis, whose main goal is to identify bacterial proteins in different IVD phylotypes that may be acting as inflammatory and nocigenic triggers.

The use of multiomic techniques, in addition to culture isolation techniques, is the most modern strategy for identifying biomarkers related to bacterial activity [51,54–60]. Summarizing the complex cellular mechanisms of restricted groups of molecules is an arduous task that involves numerous stages of analysis, data processing, and clinical validation of results. This task is even more difficult because of the global scarcity of research centers that gather such data. For the population of interest in this manuscript, the identification of a biomarker that could be non-invasively isolated from peripheral blood or urine, for example, would avoid the failure of surgical interventions, thus allowing for more effective treatment of LBP. This is indeed a strong justification for us to follow this protocol, encouraging us to share our results and to motivate the performance of other studies in this area, which is home to one of the most prevalent complaints in the areas of pain and spinal surgery. In conclusion, *C. acnes* is a pathogen that causes a low-grade symptom infection which is difficult to be diagnosed, especially in our country. This is the first study to demonstrate the isolation of *C. acnes* and phylotypes in the disc content of

patients with LBP. With the increasing number of cases involving this pathogen, particularly in orthopedic surgeries related to nonspecific infection, low immune response, and chronic pain, there is an urgent need for new biomarkers to improve not only the presence of *C. acnes* but its relation to the infectious disease. As a result, the “omics” approach can aid in the development of new diagnostic approaches for detecting *C. acnes* and assisting clinicians in infection and chronic pain in their patients.

Author Contributions: Conceptualization, V.M.d.R., C.O.G.X.L., K.-U.L., E.d.O.F. and R.K.A.F.; methodology, V.M.d.R., C.O.G.X.L. and E.d.O.F.; software, K.M.C.; validation, V.M.d.R. and R.K.A.F.; formal analysis, C.O.G.X.L., G.B.C., E.d.O.F. and K.M.C.; investigation, V.M.d.R., C.O.G.X.L., G.B.C. and E.d.O.F.; resources, V.M.d.R. and C.O.G.X.L.; writing—original draft preparation, V.M.d.R. and C.O.G.X.L.; writing—review and editing, V.M.d.R., E.d.O.F., K.-U.L. and R.K.A.F.; supervision, K.-U.L., R.K.A.F. and R.K.A.F.; project administration, V.M.d.R.; funding acquisition, E.d.O.F. All authors have read and agreed to the published version of the manuscript.

Funding: This research is being funded by Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)—Grant code E-26/211.554/2019.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Research Ethics Committee of the Gaffrée and Guinle University Hospital (CAAE: 50077521.0.0000.5258—September 2021) and at [Clinicaltrials.gov](https://clinicaltrials.gov) platform (NCT05090553—August 2021).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The research protocol is available at [Clinicaltrials.gov](https://clinicaltrials.gov), and it is also ‘in press’ at an indexed scientific journal [37].

Acknowledgments: We are grateful to the medical and nursing staff from São Matheus Hospital for supporting us in sample collection and clinical follow-up of patients; we also would like to thank the laboratory staff that is working hard to make this study possible.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Knezevic, N.N.; Candido, K.D.; Vlaeyen, J.W.S.; Van Zundert, J.; Cohen, S.P. Low back pain. *Lancet* **2021**, *398*, 78–92. [[CrossRef](#)] [[PubMed](#)]
2. James, S.L.; Abate, D.; Abate, K.H.; Abay, S.M.; Abbafati, C.; Abbasi, N.; Abbastabar, H.; Abd-Allah, F.; Abdela, J.; Abdelalim, A.; et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. *Lancet* **2018**, *392*, 1789–1858. [[CrossRef](#)] [[PubMed](#)]
3. Hartvigsen, J.; Hancock, M.J.; Kongsted, A.; Louw, Q.; Ferreira, M.L.; Genevay, S.; Hoy, D.; Karppinen, J.; Pransky, G.; Sieper, J.; et al. What low back pain is and why we need to pay attention. *Lancet* **2018**, *391*, 2356–2367. [[CrossRef](#)] [[PubMed](#)]
4. De David, C.N.; Deligne, L.D.M.C.; Da Silva, R.S.; Malta, D.C.; Duncan, B.B.; Passos, V.M.D.A.; Cousin, E. The burden of low back pain in Brazil: Estimates from the Global Burden of Disease 2017 Study. *Popul. Health Metrics* **2020**, *18*, 12. [[CrossRef](#)] [[PubMed](#)]
5. Vasconcelos, F.H.; De Araújo, G.C. Prevalence of chronic pain in Brazil: A descriptive study. *Braz. J. Pain* **2018**, *1*. [[CrossRef](#)]
6. Maher, C.; Underwood, M.; Buchbinder, R. Non-specific low back pain. *Lancet* **2017**, *389*, 736–747. [[CrossRef](#)]
7. Patrick, N.; Emanski, E.; Knaub, M.A. Acute and Chronic Low Back Pain. *Med. Clin. N. Am.* **2014**, *98*, 777–789. [[CrossRef](#)] [[PubMed](#)]
8. Vrbanić, T.S.-L. [Low back pain—from definition to diagnosis]. *Reumatizam* **2011**, *58*, 105–107. [[PubMed](#)]
9. Andersson, G.B. Epidemiological features of chronic low-back pain. *Lancet* **1999**, *354*, 581–585. [[CrossRef](#)]
10. Manniche, C.; Hall, G.M. Chronic low back pain, Modic changes and low-grade virulent infection: Efficacy of antibiotic treatment. *Futur. Sci. OA* **2021**, *7*, FSO703. [[CrossRef](#)]
11. Bivona, L.J.; Camacho, J.E.; Usmani, F.; Nash, A.; Bruckner, J.J.; Hughes, M.; Bhandutia, A.K.; Koh, E.Y.; Banagan, K.E.; Gelb, D.E.; et al. The Prevalence of Bacterial Infection in Patients Undergoing Elective ACDF for Degenerative Cervical Spine Conditions: A Prospective Cohort Study With Contaminant Control. *Glob. Spine J.* **2021**, *11*, 13–20. [[CrossRef](#)]
12. Tang, G.; Chen, Y.; Chen, J.; Wang, Z.; Jiang, W. Higher proportion of low-virulence anaerobic bacterial infection in young patients with intervertebral disc herniation. *Exp. Ther. Med.* **2019**, *18*, 3085–3089. [[CrossRef](#)] [[PubMed](#)]

13. Manniche, C.; O'Neill, S. New insights link low-virulent disc infections to the etiology of severe disc degeneration and Modic changes. *Futur. Sci. OA* **2019**, *5*, FSO389. [[CrossRef](#)]
14. Tang, G.; Wang, Z.; Chen, J.; Zhang, Z.; Qian, H.; Chen, Y. Latent infection of low-virulence anaerobic bacteria in degenerated lumbar intervertebral discs. *BMC Musculoskelet. Disord.* **2018**, *19*, 445. [[CrossRef](#)] [[PubMed](#)]
15. Chen, Y.; Wang, X.; Zhang, X.; Ren, H.; Huang, B.; Chen, J.; Liu, J.; Shan, Z.; Zhu, Z.; Zhao, F. Low virulence bacterial infections in cervical intervertebral discs: A prospective case series. *Eur. Spine J.* **2018**, *27*, 2496–2505. [[CrossRef](#)] [[PubMed](#)]
16. Ganko, R.; Rao, P.J.; Phan, K.; Mobbs, R.J. Can Bacterial Infection by Low Virulent Organisms Be a Plausible Cause for Symptomatic Disc Degeneration? A Systematic Review. *Spine* **2015**, *40*, E587–E592. [[CrossRef](#)] [[PubMed](#)]
17. Mackenzie, W.S.; Matsumoto, H.; Williams, B.A.; Corona, J.; Lee, C.; Cody, S.R.; Covington, L.; Saiman, L.; Flynn, J.M.; Skaggs, D.L.; et al. Surgical Site Infection Following Spinal Instrumentation for Scoliosis. *J. Bone Jt. Surg.* **2013**, *95*, 800–806. [[CrossRef](#)]
18. Albert, H.B.; Sorensen, J.S.; Christensen, B.S.; Manniche, C. Antibiotic treatment in patients with chronic low back pain and vertebral bone edema (Modic type 1 changes): A double-blind randomized clinical controlled trial of efficacy. *Eur. Spine J.* **2013**, *22*, 697–707. [[CrossRef](#)] [[PubMed](#)]
19. Senker, W.; Aspalter, S.; Radl, C.; Pichler, J.; Doppler, S.; Weis, S.; Webersinke, C.; Wagner, H.; Hermann, P.; Aichholzer, M.; et al. Frequency and characteristics of bacterial and viral low-grade infections of the intervertebral discs: A prospective, observational study. *J. Orthop. Traumatol.* **2022**, *23*, 15. [[CrossRef](#)]
20. Capoor, M.N.; Ruzicka, F.; Machackova, T.; Jancalek, R.; Smrcka, M.; Schmitz, J.E.; Hermanova, M.; Sana, J.; Michu, E.; Baird, J.C.; et al. Prevalence of Propionibacterium acnes in Intervertebral Discs of Patients Undergoing Lumbar Microdiscectomy: A Prospective Cross-Sectional Study. *PLoS ONE* **2016**, *11*, e0161676. [[CrossRef](#)]
21. Iyer, S.; Louie, P.K.; Nolte, M.T.; Phillips, F.M. The Relationship Between Low-Grade Infection and Degenerative Disk Disease. *J. Am. Acad. Orthop. Surg.* **2019**, *27*, 509–518. [[CrossRef](#)]
22. Georgy, M.; Vaida, F.; Stern, M.; Murphy, K. Association between Type 1 Modic Changes and Propionibacterium Acnes Infection in the Cervical Spine: An Observational Study. *Am. J. Neuroradiol.* **2018**, *39*, 1764–1767. [[CrossRef](#)]
23. Schroeder, G.D.; Markova, D.Z.; Koerner, J.D.; Rihn, J.A.; Hilibrand, A.S.; Vaccaro, A.R.; Anderson, D.G.; Kepler, C.K. Are Modic changes associated with intervertebral disc cytokine profiles? *Spine J.* **2017**, *17*, 129–134. [[CrossRef](#)] [[PubMed](#)]
24. Mirzaaghazadeh, J.; Salehpour, F.; Ziaei, E.; Javanshir, N.; Samadi, A.; Sadeghi, J.; Mirzaei, F.; Alavi, S.A.N. Modic changes in the adjacent vertebrae due to disc material infection with Propionibacterium acnes in patients with lumbar disc herniation. *Eur. Spine J.* **2017**, *26*, 3129–3134. [[CrossRef](#)]
25. Ohtori, S.; Koshi, T.; Yamashita, M.; Yamauchi, K.; Inoue, G.; Suzuki, M.; Takaso, M.; Orita, S.; Eguchi, Y.; Ochiai, N.; et al. Existence of pyogenic spondylitis in Modic type 1 change without other signs of infection: 2-year follow-up. *Eur. Spine J.* **2010**, *19*, 1200–1205. [[CrossRef](#)] [[PubMed](#)]
26. Zhang, Y.-H.; Zhao, C.-Q.; Jiang, L.-S.; Chen, X.-D.; Dai, L.-Y. Modic changes: A systematic review of the literature. *Eur. Spine J.* **2008**, *17*, 1289–1299. [[CrossRef](#)]
27. Albert, H.; Kjaer, P.; Jensen, T.S.; Sorensen, J.; Bendix, T.; Manniche, C. Modic changes, possible causes and relation to low back pain. *Med. Hypotheses* **2008**, *70*, 361–368. [[CrossRef](#)] [[PubMed](#)]
28. Yan, M.; Song, Z.; Kou, H.; Shang, G.; Shang, C.; Chen, X.; Ji, Y.; Bao, D.; Cheng, T.; Li, J.; et al. New Progress in Basic Research of Macrophages in the Pathogenesis and Treatment of Low Back Pain. *Front. Cell Dev. Biol.* **2022**, *10*, 866857. [[CrossRef](#)]
29. Li, J.; Chen, Y.; Wu, H.; Shan, Z.; Bei, D.; Gan, K.; Liu, J.; Zhang, X.; Chen, B.; Chen, J.; et al. Different responses of cervical intervertebral disc caused by low and high virulence bacterial infection: A comparative study in rats. *Bioengineered* **2022**, *13*, 12446–12461. [[CrossRef](#)]
30. Rajasekaran, S.; Tangavel, C.; Aiyer, S.N.; Nayagam, S.M.; Raveendran, M.; Demonte, N.L.; Subbaiah, P.; Kanna, R.; Shetty, A.P.; Dharmalingam, K. ISSLS PRIZE IN CLINICAL SCIENCE 2017: Is infection the possible initiator of disc disease? An insight from proteomic analysis. *Eur. Spine J.* **2017**, *26*, 1384–1400. [[CrossRef](#)]
31. Capoor, M.; Konieczna, A.; McDowell, A.; Ruzicka, F.; Smrcka, M.; Jancalek, R.; Maca, K.; Lujc, M.; Ahmed, F.; Birkenmaier, C.; et al. Pro-Inflammatory and Neurotrophic Factor Responses of Cells Derived from Degenerative Human Intervertebral Discs to the Opportunistic Pathogen Cutibacterium acnes. *Int. J. Mol. Sci.* **2021**, *22*, 2347. [[CrossRef](#)] [[PubMed](#)]
32. Shan, Z.; Wang, X.; Zong, W.; Li, J.; Zheng, B.; Huang, B.; Zhang, X.; Chen, J.; Huang, Y. The Effect of Cutibacterium acnes Infection on Nerve Penetration in the Annulus Fibrosus of Lumbar Intervertebral Discs via Suppressing Oxidative Stress. *Oxidative Med. Cell. Longev.* **2022**, *2022*, 9120674. [[CrossRef](#)]
33. Mayslich, C.; Grange, P.A.; Castela, M.; Marcelin, A.G.; Calvez, V.; Dupin, N. Characterization of a Cutibacterium acnes Camp Factor 1-Related Peptide as a New TLR-2 Modulator in In Vitro and Ex Vivo Models of Inflammation. *Int. J. Mol. Sci.* **2022**, *23*, 5065. [[CrossRef](#)]
34. Lan, W.; Wang, X.; Tu, X.; Hu, X.; Lu, H. Different phylotypes of Cutibacterium acnes cause different modic changes in intervertebral disc degeneration. *PLoS ONE* **2022**, *17*, e0270982. [[CrossRef](#)]
35. Zheng, Y.; Lin, Y.; Chen, Z.; Jiao, Y.; Yuan, Y.; Li, C.; Xu, X.; Cao, P. Propionibacterium acnes induces intervertebral discs degeneration by increasing MMP-1 and inhibiting TIMP-1 expression via the NF-kappaB pathway. *Int. J. Clin. Exp. Pathol.* **2018**, *11*, 3445–3453. [[PubMed](#)]

36. Lin, Y.; Jiao, Y.; Yuan, Y.; Zhou, Z.; Zheng, Y.; Xiao, J.; Li, C.; Chen, Z.; Cao, P. *Propionibacterium acnes* induces intervertebral disc degeneration by promoting nucleus pulposus cell apoptosis via the TLR2/JNK/mitochondrial-mediated pathway. *Emerg. Microbes Infect.* **2018**, *7*, 1–8. [[CrossRef](#)] [[PubMed](#)]
37. Da Rocha, V.M.; Lima, C.O.G.X.; Ferreira, E.D.O.; de Farias, G.C.; Nogueira, F.C.S.; Antunes, L.C.M.; Cassiano, K.M.; Fiorelli, R.K.A. Colonization of intervertebral discs by *Cutibacterium acnes* in patients with low back pain: Protocol for an analytical study with microbiological, phenotypic, genotypic, and multiomic techniques. *PLoS ONE* **2022**, *18*, e0271773. [[CrossRef](#)]
38. McDowell, A.; Barnard, E.; Nagy, I.; Gao, A.; Tomida, S.; Li, H.; Eady, A.; Cove, J.; Nord, C.E.; Patrick, S. An Expanded Multilocus Sequence Typing Scheme for *Propionibacterium acnes*: Investigation of ‘Pathogenic’, ‘Commensal’ and Antibiotic Resistant Strains. *PLoS ONE* **2012**, *7*, e41480. [[CrossRef](#)]
39. Leheste, J.R.; Ruvolo, K.E.; Chrostowski, J.E.; Rivera, K.; Husko, C.; Miceli, A.; Selig, M.K.; Brüggemann, H.; Torres, G.P. *acnes*-Driven Disease Pathology: Current Knowledge and Future Directions. *Front. Cell. Infect. Microbiol.* **2017**, *7*, 81. [[CrossRef](#)]
40. Rollason, J.; McDowell, A.; Albert, H.B.; Barnard, E.; Worthington, T.; Hilton, A.C.; Vernallis, A.; Patrick, S.; Elliott, T.; Lambert, P. Genotypic and Antimicrobial Characterisation of *Propionibacterium acnes* Isolates from Surgically Excised Lumbar Disc Herniations. *BioMed. Res. Int.* **2013**, *2013*, 530382. [[CrossRef](#)]
41. Gharanti, A.A.; Kanafani, Z.A. *Cutibacterium* (formerly *Propionibacterium*) *acnes* infections associated with implantable devices. *Expert Rev. Anti-Infect. Ther.* **2017**, *15*, 1083–1094. [[CrossRef](#)] [[PubMed](#)]
42. Mayslich, C.; Grange, P.; Dupin, N. *Cutibacterium acnes* as an Opportunistic Pathogen: An Update of Its Virulence-Associated Factors. *Microorganisms* **2021**, *9*, 303. [[CrossRef](#)] [[PubMed](#)]
43. Nazipi, S.; Stødkilde, K.; Scavenius, C.; Brüggemann, H. The Skin Bacterium *Propionibacterium acnes* Employs Two Variants of Hyaluronate Lyase with Distinct Properties. *Microorganisms* **2017**, *5*, 57. [[CrossRef](#)] [[PubMed](#)]
44. Lheure, C.; Grange, P.A.; Ollagnier, G.; Morand, P.; Désiré, N.; Sayon, S.; Corvec, S.; Raingeaud, J.; Marcelin, A.-G.; Calvez, V.; et al. TLR-2 Recognizes *Propionibacterium acnes* CAMP Factor 1 from Highly Inflammatory Strains. *PLoS ONE* **2016**, *11*, e0167237. [[CrossRef](#)]
45. Wang, Y.; Che, M.; Xin, J.; Zheng, Z.; Li, J.; Zhang, S. The role of IL-1 β and TNF- α in intervertebral disc degeneration. *Biomed. Pharmacother.* **2020**, *131*, 110660. [[CrossRef](#)]
46. Slaby, O.; McDowell, A.; Brüggemann, H.; Raz, A.; Demir-Deviren, S.; Freemont, T.; Lambert, P.; Capoor, M.N. Is IL-1 β Further Evidence for the Role of *Propionibacterium acnes* in Degenerative Disc Disease? Lessons From the Study of the Inflammatory Skin Condition Acne Vulgaris. *Front. Cell. Infect. Microbiol.* **2018**, *8*, 272. [[CrossRef](#)]
47. Zhao, H.; Yu, X.; Tang, X.S.; He, F.; Yang, Y.D.; Xiong, Y.; Hu, Z.G.; Xu, L. [Relationship between inflammatory cytokines of IL-1beta and TNF-alpha and intervertebral disc degeneration]. *Zhongguo Gu Shang* **2017**, *30*, 866–871. [[CrossRef](#)]
48. Johnson, Z.; Schoepflin, Z.; Choi, H.; Shapiro, I.; Risbud, M. Disc in flames: Roles of TNF- α and IL-1 β in intervertebral disc degeneration. *Eur. Cells Mater.* **2015**, *30*, 104–117. [[CrossRef](#)]
49. Capoor, M.N.; Ruzicka, F.; Sandhu, G.; Rollason, J.; Mavrommatis, K.; Ahmed, F.S.; Schmitz, J.E.; Raz, A.; Brüggemann, H.; Lambert, P.A.; et al. Importance of *Propionibacterium acnes* hemolytic activity in human intervertebral discs: A microbiological study. *PLoS ONE* **2018**, *13*, e0208144. [[CrossRef](#)] [[PubMed](#)]
50. Freemont, A.; Peacock, T.; Goupille, P.; Hoyland, J.; O’Brien, J.; Jayson, M. Nerve ingrowth into diseased intervertebral disc in chronic back pain. *Lancet* **1997**, *350*, 178–181. [[CrossRef](#)] [[PubMed](#)]
51. Aroke, E.N.; Powell-Roach, K.L. The Metabolomics of Chronic Pain Conditions: A Systematic Review. *Biol. Res. Nurs.* **2020**, *22*, 458–471. [[CrossRef](#)]
52. Riekeberg, E.; Powers, R. New frontiers in metabolomics: From measurement to insight. *F1000Research* **2017**, *6*, 1148. [[CrossRef](#)] [[PubMed](#)]
53. Clish, C.B. Metabolomics: An emerging but powerful tool for precision medicine. *Mol. Case Stud.* **2015**, *1*, a000588. [[CrossRef](#)]
54. Johnson, C.H.; Ivanisevic, J.; Siuzdak, G. Metabolomics: Beyond biomarkers and towards mechanisms. *Nat. Rev. Mol. Cell Biol.* **2016**, *17*, 451–459. [[CrossRef](#)] [[PubMed](#)]
55. Vlahou, A.; Fountoulakis, M. Proteomic approaches in the search for disease biomarkers. *J. Chromatogr. B* **2005**, *814*, 11–19. [[CrossRef](#)] [[PubMed](#)]
56. Teckchandani, S.; Gowda, G.A.N.; Raftery, D.; Curatolo, M. Metabolomics in chronic pain research. *Eur. J. Pain* **2021**, *25*, 313–326. [[CrossRef](#)]
57. Swank, K.R.; Furness, J.E.; Baker, E.A.; Gehrke, C.K.; Biebelhausen, S.P.; Baker, K.C. Metabolomic Profiling in the Characterization of Degenerative Bone and Joint Diseases. *Metabolites* **2020**, *10*, 223. [[CrossRef](#)]
58. Qiu, C.; Wu, X.; Bian, J.; Ma, X.; Zhang, G.; Guo, Z.; Wang, Y.; Ci, Y.; Wang, Q.; Xiang, H.; et al. Differential proteomic analysis of fetal and geriatric lumbar nucleus pulposus: Immunoinflammation and age-related intervertebral disc degeneration. *BMC Musculoskelet. Disord.* **2020**, *21*, 339. [[CrossRef](#)] [[PubMed](#)]

59. Wu, X.; Xiang, H.; Zhang, G.; Hu, Y.; Wang, Y.; Chen, B. A metabolic profiling analysis of degenerative intervertebral disc disease in a rabbit model via GC/TOF-MS. *Res. Sq.* **2019**. [[CrossRef](#)]
60. Rinschen, M.M.; Ivanisevic, J.; Giera, M.; Siuzdak, G. Identification of bioactive metabolites using activity metabolomics. *Nat. Rev. Mol. Cell Biol.* **2019**, *20*, 353–367. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.